Given prior evidence that targeting Pyk2/FAK signaling enhances the efficacy of temozolomide in GBM models, investigating ethnicity-specific responses to Pyk2 inhibitors could inform the development of personalized therapeutic strategies. The gene discussed is PTK2B; the disease is glioblastoma.